MedTrace Logo

Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Controlled Trial

NCT07524335 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-05-12

No results posted yet for this study

Summary

In patients with subclinical coronary artery disease, the ASCAD-P study aims to assess the feasibility of a larger phase 3 pragmatic randomized controlled trial comparing prescription versus no prescription of low-dose aspirin in routine clinical practice.

Conditions

Interventions

DRUG

Prescription of Aspirin

Aspirin 81 mg orally once daily

DRUG

No prescription

No prescription of aspirin 81 mg orally once daily

Sponsors & Collaborators

  • Montreal Heart Institute

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2027-05-01
Completion
2028-05-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07524335 on ClinicalTrials.gov